Eriko Aotani

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial

Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto et al. · Journal of Clinical Oncology · 2016 · 144 citations

Medicine, Gynecology, Oncology +15

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up

Keiichi Fujiwara, Noriaki Sakuragi, Sachiko Suzuki et al. · Gynecologic Oncology · 2003 · 93 citations

Medicine, Gynecology, Oncology +12

Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin—A Sankai Gynecology Study Group (SGSG) study

Yasunari Miyagi, Kentaro Fujiwara, Junzo Kigawa et al. · Gynecologic Oncology · 2005 · 89 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

Madeleine King, Martin R. Stockler, Rachel O’Connell et al. · Quality of Life Research · 2017 · 58 citations

Medicine, Gynecology, Oncology +17

A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer

K. Fujiwara, Eriko Aotani, Tetsutaro Hamano et al. · Japanese Journal of Clinical Oncology · 2010 · 40 citations · Full text

Medicine, Gynecology, Oncology +17